I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

Number 4: Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, ...

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the ...

Tumor necrosis factor (TNF)-α is central to the pathology of IBD, chronic inflammatory diseases of the gastrointestinal tract. Infliximab was the first anti-TNF therapy approved for IBD, and the ...